Co-targeting this pathway using the FAK inhibitor PF562271 and the BRAF inhibitor vemurafenib could represent a promising therapeutic approach for BRAF-mutant colorectal cancer (CRC) patients, as they exhibit synergistic antitumor effects in vitro and in vivo [147]. Here, BRAF is linked to colorectal cancer.